QCM
ACAD icon

Quantinno Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Quantinno Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341K Buy
15,332
+5,244
+52% +$125K ﹤0.01% 2964
2025
Q4 		$269K Sell
10,088
-1,112
-10% -$26.6K ﹤0.01% 2894
2025
Q3 		$239K Buy
+11,200
New +$265K ﹤0.01% 2634

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Quantinno Capital Management's ACAD Position: Q1 2026 in Review

Quantinno Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 52% in Q1 2026, buying an estimated $125K and bringing the position to 15,332 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

Quantinno Capital Management first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Quantinno Capital Management held 15,332 shares of Acadia Pharmaceuticals worth $341K as of Q1 2026.
  • Quantinno Capital Management bought 5,244 Acadia Pharmaceuticals shares in Q1 2026, an estimated $125K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q1 2026, its #2964 holding.
  • Quantinno Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.